Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

被引:67
作者
Klintman, Jenny [1 ,2 ,3 ]
Appleby, Niamh [1 ,2 ,4 ]
Stamatopoulos, Basile [1 ,5 ]
Ridout, Katie [1 ,2 ]
Eyre, Toby A. [4 ]
Robbe, Pauline [1 ,2 ]
Pascua, Laura Lopez [1 ,2 ]
Knight, Samantha J. L. [6 ,7 ]
Dreau, Helene [1 ,2 ]
Cabes, Maite [4 ]
Popitsch, Niko [6 ,7 ,8 ]
Ehinger, Mats [9 ]
Martin-Subero, Jose I. [10 ,11 ]
Campo, Elias [10 ]
Mansson, Robert [12 ,13 ]
Rossi, Davide [14 ]
Taylor, Jenny C. [6 ,7 ]
Vavoulis, Dimitrios V. [1 ,2 ,6 ,7 ]
Schuh, Anna [1 ,2 ,4 ,6 ]
机构
[1] Univ Oxford, Dept Oncol, Mol Diagnost Ctr, Oxford, England
[2] Univ Oxford, Dept Oncol, Oxford, England
[3] Lund Univ, Skane Univ Hosp, Dept Translat Med, Lund, Sweden
[4] Oxford Univ Hosp Natl Hlth Serv NHS Trust, Dept Hematol, Oxford, England
[5] Univ Libre Bruxelles ULB, Inst Jules Bordet, Lab Clin Cell Therapy, Brussels, Belgium
[6] Univ Oxford, Natl Inst Hlth Res NIHR Oxford Biomed Res Ctr, Oxford, England
[7] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England
[8] Childrens Canc Res Inst CCRI, Vienna, Austria
[9] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Pathol, Lund, Sweden
[10] Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain
[11] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
[12] Karolinska Inst, Ctr Hematol & Regenerat Med Huddinge, Stockholm, Sweden
[13] Karolinska Univ Hosp, Hematol Ctr, Stockholm, Sweden
[14] Inst Oncol Res IOR, Bellinzona, Switzerland
基金
英国惠康基金;
关键词
RNA-SEQ DATA; RECURRENT MUTATIONS; CELL-GROWTH; IBRUTINIB; RESISTANCE; PROGRESSION; OFATUMUMAB; SUPPRESSOR; EVOLUTION; OUTCOMES;
D O I
10.1182/blood.2020005650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we conducted whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 patients recruited into a clinical trial (CHOP-0). We found that tissue-RS was enriched for mutations in poor-risk CLL drivers and genes in the DNA damage response (DDR) pathway. In addition, we identified genomic aberrations not previously implicated in RS, including the protein tyrosine phosphatase receptor (PTPRD) and tumor necrosis factor receptor-associated factor 3 (TRAF3). In the noncoding genome, we discovered activation-induced cytidine deaminase related and unrelated kataegis in tissue RS affecting regulatory regions of key immune regulatory genes. These include BTG2, CXCR4, NFATC1, PAX5, NOTCH 1, SLC44A5, FCRL3, SELL, TNIP2, and TRIM13. Furthermore, differences between the global mutation signatures of pairs of PB-CLL and tissue-RS samples implicate DDR as the dominant mechanism driving transformation. Pathway-based clonal deconvolution analysis showed that genes in the MAPK and DDR pathways demonstrate high clonal-expansion probability. Direct comparison of nodal-CLL and tissue-RS pairs from an independent cohort confirmed differential expression of the same pathways by RNA expression profiling. Our integrated analysis of WGS and RNA expression data significantly extends previous targeted approaches, which were limited by the lack of germline samples, and it facilitates the identification of novel genomic correlates implicated in RS transformation, which could be targeted therapeutically. Our results inform the future selection of investigative agents for a UK clinical platform study.
引用
收藏
页码:2800 / 2816
页数:17
相关论文
共 76 条
[21]   TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity [J].
Gatt, Moshe E. ;
Takada, Kohichi ;
Mani, Mala ;
Lerner, Mikael ;
Pick, Marjorie ;
Hideshima, Teru ;
Carrasco, Daniel E. ;
Protopopov, Alexei ;
Ivanova, Elena ;
Sangfelt, Olle ;
Grander, Dan ;
Barlogie, Bart ;
Shaughnessy, John D., Jr. ;
Anderson, Kenneth C. ;
Carrasco, Daniel R. .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (02) :210-220
[22]   Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia [J].
Gimenez, Neus ;
Martinez-Trillos, Alejandra ;
Montraveta, Arnau ;
Lopez-Guerra, Monica ;
Rosich, Laia ;
Nadeu, Ferran ;
Valero, Juan G. ;
Aymerich, Marta ;
Magnano, Laura ;
Rozman, Maria ;
Matutes, Estella ;
Delgado, Julio ;
Baumann, Tycho ;
Gine, Eva ;
Gonzalez, Marcos ;
Alcoceba, Miguel ;
Jose Terol, M. ;
Navarro, Blanca ;
Colado, Enrique ;
Payer, Angel R. ;
Puente, Xose S. ;
Lopez-Otin, Carlos ;
Lopez-Guillermo, Armando ;
Campo, Elias ;
Colomer, Dolors ;
Villamor, Neus .
HAEMATOLOGICA, 2019, 104 (03) :576-586
[23]   Expanding TRAF function: TRAF3 as a tri-faced immune regulator [J].
Haecker, Hans ;
Tseng, Ping-Hui ;
Karin, Michael .
NATURE REVIEWS IMMUNOLOGY, 2011, 11 (07) :457-468
[24]   Investigating the Targets of MIR-15a and MIR-16-1 in Patients with Chronic Lymphocytic Leukemia (CLL) [J].
Hanlon, Katy ;
Rudin, Claudius E. ;
Harries, Lorna W. .
PLOS ONE, 2009, 4 (09)
[25]   Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2 [J].
Hodson, Daniel J. ;
Shaffer, Arthur L. ;
Xiao, Wenming ;
Wright, George W. ;
Schmitz, Roland ;
Phelan, James D. ;
Yang, Yandan ;
Webster, Daniel E. ;
Rui, Lixin ;
Kohlhammer, Holger ;
Nakagawa, Masao ;
Waldmann, Thomas A. ;
Staudt, Louis M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (14) :E2039-E2046
[26]   The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis [J].
Hunter, Zachary R. ;
Xu, Lian ;
Yang, Guang ;
Zhou, Yangsheng ;
Liu, Xia ;
Cao, Yang ;
Manning, Robert J. ;
Tripsas, Christina ;
Patterson, Christopher J. ;
Sheehy, Patricia ;
Treon, Steven P. .
BLOOD, 2014, 123 (11) :1637-1646
[27]   Gene set enrichment analysis made simple [J].
Irizarry, Rafael A. ;
Wang, Chi ;
Zhou, Yun ;
Speed, Terence P. .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2009, 18 (06) :565-575
[28]   Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib [J].
Jain, Preetesh ;
Thompson, Philip A. ;
Keating, Michael ;
Estrov, Zeev ;
Ferrajoli, Alessandra ;
Jain, Nitin ;
Kantarjian, Hagop ;
Burger, Jan A. ;
O'Brien, Susan ;
Wierda, William G. .
CANCER, 2017, 123 (12) :2268-2273
[29]   Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder [J].
Keller, Michael D. ;
Pandey, Rahul ;
Li, Dong ;
Glessner, Joseph ;
Tian, Lifeng ;
Henrickson, Sarah E. ;
Chinn, Ivan K. ;
Monaco-Shawver, Linda ;
Heimall, Jennifer ;
Hou, Cuiping ;
Otieno, Frederick G. ;
Jyonouchi, Soma ;
Calabrese, Leonard ;
van Montfrans, Joris ;
Orange, Jordan S. ;
Hakonarson, Hakon .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 138 (02) :544-+
[30]   A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities [J].
Kochi, Y ;
Yamada, R ;
Suzuki, A ;
Harley, JB ;
Shirasawa, S ;
Sawada, T ;
Bae, SC ;
Tokuhiro, S ;
Chang, XT ;
Sekine, A ;
Takahashi, A ;
Tsunoda, T ;
Ohnishi, Y ;
Kaufman, KM ;
Kang, CSP ;
Kang, CW ;
Otsubo, S ;
Yumura, W ;
Mimori, A ;
Koike, T ;
Nakamura, Y ;
Sasazuki, T ;
Yamamoto, K .
NATURE GENETICS, 2005, 37 (05) :478-485